Physician profile
Kali Gray
NPI 1548916224
$2,168.45
in general payments reported to CMS, 2019-2025
31 companies · $652 in 2025
The $652 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $344 · 2023: $615 · 2024: $557 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.66 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $380.76 | 2023-2025 | |
| Novo Nordisk INC | $255.58 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $195.19 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $168.20 | 2022-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.66 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Alexion Pharmaceuticals, INC. | $99.99 | 2024 | Soliris |
| Abbvie INC. | $88.70 | 2023-2025 | |
| Gilead Sciences, INC. | $76.03 | 2022-2025 | |
| Astellas Pharma US INC | $71.63 | 2024-2025 | Veozah |
| Boston Scientific Corporation | $64.10 | 2023 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $48.51 | 2022-2025 | |
| Amgen INC. | $47.47 | 2022-2024 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $46.08 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $43.42 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $42.75 | 2025 | Opsumit, Uptravi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $42.73 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $39.70 | 2022-2023 | Xarelto |
| Corcept Therapeutics | $38.00 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $30.94 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $30.51 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $29.88 | 2023 | Gemtesa |
| Pulmonx Corporation | $27.12 | 2022 | |
| Inspire Medical Systems, INC. | $22.59 | 2024 | Inspire |
| Daiichi Sankyo INC. | $22.41 | 2022 | |
| Madrigal Pharmaceuticals | $21.91 | 2024 | Resmetirom |
| Xeris Pharmaceuticals, INC. | $21.35 | 2023 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $19.53 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $19.41 | 2023 | Inpefa |
| Dynavax Technologies Corporation | $17.56 | 2024 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $14.73 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kali Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.